FG-3019/gemcitabine combined-treatment effect on KPC model of pancreatic ductal adenocarcinoma
Summary:
Analysis of PDA tumors isolated from KPC (LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre) mice after combined treatment with FG-3019 (a mAb directed against CTGF) and chemotherapy drug gemcitabine. Results provide insight into the molecular basis of the enhanced anti-PDA activity of FG-3019/gemcitabine.
Neesse A, Frese KK, Bapiro TE, Nakagawa T et al. CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer. Proc Natl Acad Sci U S A 2013 Jul 23;110(30):12325-30. PMID: 23836645
